FLT3 and acute myeloid leukemia: In pediatric AML, the most extensively studied first-generation FLT3 inhibitor is Sorafenib, which was investigated as single agent or in combination with other drugs in several formal clinical trials enrolling both de novo or refractory/relapsed AML.